Meredith McKean

3.1k total citations · 1 hit paper
118 papers, 961 citations indexed

About

Meredith McKean is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Meredith McKean has authored 118 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 50 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Meredith McKean's work include Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (28 papers) and Melanoma and MAPK Pathways (18 papers). Meredith McKean is often cited by papers focused on Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (28 papers) and Melanoma and MAPK Pathways (18 papers). Meredith McKean collaborates with scholars based in United States, United Kingdom and Australia. Meredith McKean's co-authors include Rodabe N. Amaria, Daniel P. Petrylak, Haolan Lu, Elmer Berghorn, Richard Gedrich, Anthony W. Tolcher, Jennifer L. McQuade, Douglas B. Johnson, Caressa Lietman and Kathryn E. Beckermann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Meredith McKean

107 papers receiving 946 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

2022 125 citations Meredith McKean et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meredith McKean United States	16	591	483	238	137	75	118	961
Amy Weise United States	19	530 0.9×	438 0.9×	191 0.8×	259 1.9×	59 0.8×	69	946
Jennifer E. Howes United States	11	280 0.5×	404 0.8×	170 0.7×	115 0.8×	56 0.7×	12	854
K. Papadopoulos United States	16	540 0.9×	598 1.2×	299 1.3×	215 1.6×	48 0.6×	56	1.1k
Luigi Manenti United States	10	470 0.8×	332 0.7×	284 1.2×	115 0.8×	32 0.4×	20	886
J. Rafael Sierra United States	11	364 0.6×	582 1.2×	195 0.8×	249 1.8×	76 1.0×	18	1.1k
Takafumi Koyama Japan	19	447 0.8×	293 0.6×	136 0.6×	168 1.2×	30 0.4×	87	871
Brian Riesenberg United States	13	356 0.6×	317 0.7×	321 1.3×	85 0.6×	91 1.2×	17	857
Nyam Kamsu-Kom France	10	615 1.0×	662 1.4×	101 0.4×	117 0.9×	23 0.3×	12	1.0k
M. Thomas France	8	758 1.3×	503 1.0×	238 1.0×	172 1.3×	23 0.3×	20	1.1k
A. W. Tolcher United States	19	583 1.0×	821 1.7×	168 0.7×	310 2.3×	59 0.8×	107	1.3k

Countries citing papers authored by Meredith McKean

Since Specialization

Citations

This map shows the geographic impact of Meredith McKean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meredith McKean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meredith McKean more than expected).

Fields of papers citing papers by Meredith McKean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meredith McKean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meredith McKean. The network helps show where Meredith McKean may publish in the future.

Co-authorship network of co-authors of Meredith McKean

This figure shows the co-authorship network connecting the top 25 collaborators of Meredith McKean. A scholar is included among the top collaborators of Meredith McKean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meredith McKean. Meredith McKean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, Ryan J., J.C. Hassel, Teresa Amaral, et al.. (2025). 954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001). Annals of Oncology. 36. S585–S585.

Papadopoulos, Kyriakos P., Meredith McKean, Silvia Goldoni, et al.. (2024). First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A. Clinical Cancer Research. 30(24). 5568–5576. 3 indexed citations

Butler, Marcus O., Ryan Weight, Rizwan Haq, et al.. (2024). 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. Annals of Oncology. 35. S747–S747. 2 indexed citations

Wainberg, Zev A., Yongjun Cha, Jasmaninder Singh Grewal, et al.. (2024). 659P Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer. Annals of Oncology. 35. S519–S520. 3 indexed citations

Olson, Daniel G., Afshin Dowlati, Jason J. Luke, et al.. (2024). 1004P Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors. Annals of Oncology. 35. S683–S683.

McKean, Meredith, Òscar Reig, Elisa Fontana, et al.. (2024). 654P Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors. Annals of Oncology. 35. S517–S517. 1 indexed citations

Long, Georgina V., Victoria Atkinson, Paolo A. Ascierto, et al.. (2024). A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).. Journal of Clinical Oncology. 42(16_suppl). TPS9602–TPS9602. 3 indexed citations

McKean, Meredith, Leslie R. DeMars, Mengyao Li, et al.. (2024). Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs).. Journal of Clinical Oncology. 42(16_suppl). 3088–3088. 2 indexed citations

Vaishampayan, Ulka N., Randy F. Sweis, Deepak Kilari, et al.. (2024). Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.. Journal of Clinical Oncology. 42(16_suppl). 2507–2507. 1 indexed citations

10.

Fontana, Emily, Meredith McKean, Raid Aljumaily, et al.. (2024). 647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study. Annals of Oncology. 35. S511–S512.

11.

Falchook, Gerald S., Robert Wesolowski, Hatem Soliman, et al.. (2024). 658P First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors. Annals of Oncology. 35. S519–S519. 2 indexed citations

12.

Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(4). 1100–1110. 11 indexed citations

13.

Cassier, Philippe A., Janice M. Mehnert, Richard D. Kim, et al.. (2024). 613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors. Annals of Oncology. 35. S491–S492. 2 indexed citations

14.

Khattak, Adnan, Jeffrey S. Weber, Tarek Meniawy, et al.. (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.. Journal of Clinical Oncology. 41(17_suppl). LBA9503–LBA9503. 50 indexed citations

15.

Lee, Elizabeth, Jordi Rodón, Michael J. Demeure, et al.. (2023). Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300). Gynecologic Oncology. 176. S185–S185. 1 indexed citations

16.

Panella, Timothy J., Sajeve Thomas, Meredith McKean, et al.. (2023). A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.. Journal of Clinical Oncology. 41(16_suppl). TPS9598–TPS9598. 1 indexed citations

17.

Weber, Jeffrey S., Adnan Khattak, Matteo S. Carlino, et al.. (2023). LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. Annals of Oncology. 34. S1288–S1289. 5 indexed citations

18.

Schadendorf, Dirk, Reinhard Dummer, Caroline Robert, et al.. (2022). STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncology. 18(17). 2041–2051. 12 indexed citations

19.

McKean, Meredith & Rodabe N. Amaria. (2018). Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. American Journal of Clinical Dermatology. 19(5). 639–646. 1 indexed citations

20.

Rai, Robba, Jennifer L. McQuade, Jeffrey A. Sosman, et al.. (2016). Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma. Annals of Oncology. 27. vi381–vi381. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact